Insider buying last 90 days
No open-market insider purchases were filed for JNJ in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every JNJ insider filing, plotted on the chart in Gekko.Open JNJ in Gekko
NYSE: JNJ
Johnson & Johnson (JNJ) Stock Analysis & Forecast
Nov 4 close
$276.32+10.15 (+3.8%)
Gekko Brief
AI summaryNov 4 closeThis week's news centers on Johnson & Johnson's DePuy Synthes orthopedics unit, as Smith+Nephew confirmed that merger talks between the two companies have ended, reportedly over disagreements on leadership of the combined group. The discussions had reportedly valued J&J's orthopaedics unit at up to $22 billion. Separately, J&J disclosed new real-world data for its Impella heart pump showing reduced mortality rates in high-risk coronary procedures, supporting the ongoing PROTECT IV trial and the company's MedTech expansion narrative. Commentary also circulated questioning whether JNJ shares look expensive on current price-to-earnings and price-to-sales ratios relative to forecasted 2026 and 2027 profits.
JNJ closed at $276.32, up 3.8%, and sits above both its 50-day average of $265.53 and 200-day average of $247.77, with the 50-day above the 200-day. The stock's one-month return is 8.5% and its one-year return is 48.4%, with shares trading near the 52-week high of $282.02. The GekkoIndex reads 49.8, placing it in the Neutral zone, down 1.7 over five days. Gekko Fair Value stands at $281.21, putting price 1.7% below that mark.
Over the next 20 trading days, the next earnings date falls on 26 January 2027, 82 days out and beyond a typical holding window. In the last 90 days, Congress recorded 3 buys and 0 sells. Seasonality for this point in the calendar shows a 2.5% average 20-day return over 5 years, with gains in 3 of those years. The prior earnings reaction, on 13 October 2026, moved shares -3.7% despite an EPS beat of $2.59 versus $2.52 estimated.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Johnson & Johnson price vs fair value
Close $276.32200-day averageGekko Fair Value $281.21
Johnson & Johnson quick facts
- Market cap
- $665.2B
- P/E ratio
- 41.1
- Forward P/E
- 23
- EPS, TTM
- $6.59
- Revenue, TTM
- $99.33B
- Profit margin
- 16.2%
- Dividend yield
- 1.93%
- Beta
- 0.20
- Volume
- 9.54M avg 7.65M
- 1-year return
- +48.4%
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±3.4%
- 50-day average
- $265.53
- 200-day average
- $247.77
- Next earnings
- Jan 26 before open
- Shares outstanding
- 2.41B
Johnson & Johnson swing-trade checklist
Johnson & Johnson scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $276.32 is above the 50-day ($265.53) and 200-day ($247.77) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
49.8, Neutral
Reading 49.8 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
1.7% below
Price is within 5% of Gekko Fair Value (1.7% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 3 buys / 0 sales.
See smart money - Earnings risksupportive
Reports in 82 days
Next report Jan 26, 2027, 82 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+2.5% on average
From this point in the calendar, the next 20 trading days averaged +2.5% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Johnson & Johnson stock chart and price history
Johnson & Johnson closed at $276.32 on Nov 4, 2026, +48.4% over the past year, inside a 52-week range of $185.12 to $282.02.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +8.5%
- 3 months
- +7.5%
- 6 months
- +23.0%
- 1 year
- +48.4%
The full JNJ chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open JNJ in Gekko
Follow Johnson & Johnson through every session
Put JNJ on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track JNJ in GekkoFree for 7 days. No credit card required.
About Johnson & Johnson
Johnson & Johnson operates as a holding company centered on healthcare, covering the research, development, manufacturing, and sale of related products. It is best known for its broad reach across medical fields rather than a single product line, spanning treatments and devices used in patient care.
The business is structured into two segments. Innovative Medicine covers areas such as immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolic conditions, and pulmonary hypertension. MedTech supplies products for interventional solutions, orthopaedics, surgery, and vision, forming a separate line of offerings within the company.
Johnson & Johnson traces its founding back to 1887, established by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. It is headquartered in New Brunswick, New Jersey, and its shares are listed on the NYSE under the ticker JNJ.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- jnj.com
Johnson & Johnson GekkoIndex: the smart money zone
Johnson & Johnson’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 49.8, in the Neutral zone, down 1.7 points over five sessions.
49.8Neutral
Down 1.7 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 36 | +0.2% | +0.2% | ||
| Accumulation | 173 | +0.5% | +1.5% | ||
| Neutral (current zone) | 402 | +0.3% | +1.7% | ||
| Distribution | 83 | +0.8% | +2.1% | ||
| Selling | 3 | Too few readings yet | |||
Average JNJ share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the JNJ price, zone by zone.Track JNJ in Gekko
Is Johnson & Johnson stock overvalued? Gekko Fair Value
Johnson & Johnson trades 1.7% below Gekko Fair Value of $281.21, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Johnson & Johnson shares are worth, recalculated every trading day.
$281.21
Gekko Fair Value, Nov 4, 2026
1.7% below fair value · About fair value
At the end of Aug 2026 the price was 6.9% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open JNJ in Gekko
Johnson & Johnson insider and Congress trading
No open-market insider purchases were filed for Johnson & Johnson, and members of Congress disclosed 3 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
3trades disclosed: 3 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 25 |
| Lloyd Doggett House, TX, purchase | $1,001 - $15,000 | Oct 6 traded Sep 8 |
| Ro Khanna House, CA, purchase | $15,001 - $50,000 | Oct 9 traded Sep 4 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Johnson & Johnson has been buying back its own shares.
- Bought back, quarter ended Sep 27, 2026
- $1.71B
- As a share of market cap
- 0.26%
- Trailing four quarters
- $7.88B
From company filings.
Hedge funds and billionaires quarter ended Mar 31
0of the funds Gekko tracks hold JNJ.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Johnson & Johnson earnings: next date and track record
Johnson & Johnson reports on Jan 26, 2027, before the open (82 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Jan 26, 2027
Expected before the open, 82 days away
- EPS estimate
- $2.91
- Revenue estimate
- $26.41B
7 of 8reports beat the EPS estimate
±1.5%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 13, 2026 AI summary
- What they said
- JNJ reported Q3 2026 operational sales growth of 6%, with quarterly sales exceeding $25 billion, tracking toward a historic first $100 billion annual revenue milestone. Innovative Medicine grew 7.9% operationally with 8 double-digit growing brands. Oncology surged 17%, driven by multiple myeloma dominance, RYBREVANT +64%, and INLEXZO capturing ~33% new patient share in bladder cancer. Tremfya achieved 68% growth, becoming the #1 IL-23 inhibitor across multiple indications.
- Guidance
- Management reaffirmed 2026 full-year guidance, projecting revenue to exceed $100 billion for the first time in company history. JNJ targets double-digit growth by decade-end and oncology sales exceeding $50 billion by 2030.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 13, 2026 | $2.59 est $2.52 | $25.40B est $25.38B | −3.7% |
| Jul 15, 2026 | $2.90 est $2.84 | $25.31B est $25.06B | −1.5% |
| Apr 14, 2026 | $2.70 est $2.68 | $24.06B est $23.61B | +0.3% |
| Jan 21, 2026 | $2.46 est $2.46 | $24.56B est $24.15B | +0.1% |
| Oct 14, 2025 | $2.80 est $2.76 | $23.99B est $23.76B | +0.1% |
| Jul 16, 2025 | $2.77 est $2.68 | $23.74B est $22.85B | +5.0% |
| Apr 15, 2025 | $2.77 est $2.58 | $21.89B est $21.56B | −0.3% |
| Jan 22, 2025 | $2.04 est $1.99 | $22.52B est $22.43B | −1.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Johnson & Johnson stock forecast and analyst price targets
Analysts’ average 12-month price target for Johnson & Johnson is $279.41, +1.1% from the last close, from 18 firms rating the stock in the last 90 days.
$279.41consensus 12-month target, +1.1% from the last close
Now $276.32Avg $279.41
Low $110High $320
Each firm’s latest rating in the last 90 days: 18 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 27 | RBC Capital | $280 | +1.3% |
| Oct 27 | Leerink Partners | $272 | −1.6% |
| Oct 26 | Scotiabank | $305 | +10.4% |
| Oct 26 | Goldman Sachs | $280 | +1.3% |
| Oct 25 | UBS | $320 | +15.8% |
+1.7%average 20-day move after past Neutral readings
+2.5%average move over the next 20 trading days in the last 5 years
±2.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Johnson & Johnson seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Johnson & Johnson averaged +2.5% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.6% | 1 of 5 |
| Next 10 trading days | +1.1% | 2 of 5 |
| Next 15 trading days | +1.8% | 2 of 5 |
| Next 20 trading days | +2.5% | 3 of 5 |
| Next 30 trading days | +2.5% | 4 of 5 |
For scale, JNJ’s typical 20-trading-day move in either direction is about 3.4%.
Johnson & Johnson market cap and key statistics
Johnson & Johnson’s market cap is $665.2B, with a P/E ratio of 41.1 and revenue of $99.33B over the last twelve months.
Valuation
- Market cap
- $665.2B
- P/E ratio
- 41.1
- Forward P/E
- 23
- EPS, TTM
- $6.59
- Gekko Fair Value
- $281.21
Trading
- Volume
- 9.54M
- Avg volume, 20 days
- 7.65M
- 52-week high
- $282.02
- 52-week low
- $185.12
- Shares outstanding
- 2.41B
Financials
- Revenue, TTM
- $99.33B
- Profit margin
- 16.2%
- Return on equity
- 20%
- Quarterly earnings growth, YoY
- −95.9%
Risk and income
- Beta
- 0.20
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±3.4%
- Dividend yield
- 1.93%
Johnson & Johnson stock news this week
Coverage of Johnson & Johnson this week reads positive: 9 positive, 4 neutral and 1 negative headlines.
- Smith+Nephew held failed talks with J&J over potential orthopedics combinationFierce Biotech, Nov 4
- If Johnson & Johnson Stock Looks Expensive, You Need To Read ThisTrefis, Nov 4
- Smith+Nephew Drops Its Outlook As J&J Talks EndFinimize, Nov 4
- Smith+Nephew cuts outlook after failed orthopaedics deal talks with J&JThe Lufkin Daily News, Nov 4
- Could Johnson & Johnson (JNJ) Impella Data Reshape High Risk Heart Care?Simply Wall St, Nov 4
- Johnson & Johnson $JNJ Stock Bought by BOCHK Asset Management LtdDefense World, Nov 4
Johnson & Johnson peers
Johnson & Johnson’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Distribution | 27.7% above |
| ABBVAbbVie | Neutral | 26.5% above |
| MRKMerck | Neutral | 8.6% below |
| AZNAstraZeneca | Distribution | 34.1% below |
| PFEPfizer | Neutral | 4.1% below |
| VRTXVertex Pharmaceuticals | Neutral | 16.8% above |
A peer links to its own page where one exists.
Johnson & Johnson stock FAQ
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $665.2B at the Nov 4, 2026 close of $276.32, with 2.41B shares outstanding. The shares trade on a P/E ratio of 41.1.
What is the Johnson & Johnson stock forecast?
The consensus analyst 12-month price target for Johnson & Johnson is $279.41, +1.1% from the last close. Of the 18 firms that rated the stock in the last 90 days, 11 rate it a buy, 6 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Johnson & Johnson stock overvalued or undervalued?
On Gekko’s estimate Johnson & Johnson is about fair value: the Nov 4, 2026 close of $276.32 is 1.7% below Gekko Fair Value of $281.21. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Johnson & Johnson report earnings next?
Johnson & Johnson is expected to report on Jan 26, 2027, before the market opens (82 days away). Analysts expect earnings of $2.91 per share on revenue of $26.41B. Johnson & Johnson beat the earnings estimate in 7 of its last 8 reports, moving 1.5% on average across the report.
What is Johnson & Johnson’s 52-week high and low?
Johnson & Johnson’s 52-week high is $282.02 and its 52-week low is $185.12; it closed at $276.32 on Nov 4, 2026, +48.4% over the past year.
Is Johnson & Johnson stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Johnson & Johnson the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.